ProPhase Labs, Inc. (PRPH)
- Previous Close
0.3030 - Open
0.3046 - Bid --
- Ask --
- Day's Range
0.3000 - 0.3300 - 52 Week Range
0.2200 - 5.4500 - Volume
580,993 - Avg. Volume
8,040,740 - Market Cap (intraday)
13.694M - Beta (5Y Monthly) -0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4200 - Earnings Date May 13, 2025 - May 22, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 24, 2022
- 1y Target Est
13.80
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
www.prophaselabs.com96
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRPH
View MorePerformance Overview: PRPH
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRPH
View MoreValuation Measures
Market Cap
13.69M
Enterprise Value
37.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.99
Price/Book (mrq)
1.86
Enterprise Value/Revenue
5.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.13%
Return on Equity (ttm)
-174.58%
Revenue (ttm)
6.77M
Net Income Avi to Common (ttm)
-49.52M
Diluted EPS (ttm)
-2.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
678k
Total Debt/Equity (mrq)
334.19%
Levered Free Cash Flow (ttm)
5.02M